PRN Pharmaceuticals

Principia Biopharma is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapies for immune-mediated diseases and oncology. The company utilizes its proprietary Tailored Covalency platform to design selective and reversible covalent inhibitors, which aim to provide the potency of covalent bonding with the safety of reversible binding. Its lead programs include rilzabrutinib (PRN1008) for pemphigus and immune thrombocytopenia, and tolebrutinib (PRN2246), which was licensed to Sanofi for the treatment of multiple sclerosis. Principia was acquired by Sanofi in 2020 for approximately $3.68 billion to bolster Sanofi's presence in autoimmune and inflammatory diseases.